Last $4.76 USD
Change Today +0.07 / 1.49%
Volume 519.4K
ZIOP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

ziopharm oncology inc (ZIOP) Snapshot

Open
$4.87
Previous Close
$4.69
Day High
$4.95
Day Low
$4.69
52 Week High
03/20/14 - $5.58
52 Week Low
10/8/14 - $2.31
Market Cap
488.9M
Average Volume 10 Days
992.8K
EPS TTM
$-0.30
Shares Outstanding
102.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZIOPHARM ONCOLOGY INC (ZIOP)

ziopharm oncology inc (ZIOP) Related Bloomberg News

View More Bloomberg News

ziopharm oncology inc (ZIOP) Related Businessweek News

No Related Businessweek News Found

ziopharm oncology inc (ZIOP) Details

ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the discovery and development of cancer therapies that address unmet medical needs through synthetic biology. The company is employing novel gene expression and control technology to deliver DNA for the treatment of cancer. Its technology platform employs Intrexon Corporation’s RheoSwitch Therapeutic System platform to turn on and off, and modulate gene expression at the cancer site in order to improve the therapeutic index. This technology is being evaluated in Phase II clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The company is also developing novel small molecules as potential cancer therapeutics. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

43 Employees
Last Reported Date: 03/3/14

ziopharm oncology inc (ZIOP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $600.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $230.3K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $411.3K
Advisor
Total Annual Compensation: $206.3K
Compensation as of Fiscal Year 2013.

ziopharm oncology inc (ZIOP) Key Developments

ZIOPHARM Oncology, Inc. and Intrexon Corporation Present Clinical and Preclinical Data from Immuno-Oncology Programs at AACR Tumor Immunology and Immunotherapy Meeting

ZIOPHARM Oncology, Inc. and Intrexon Corporation announced the presentation of clinical and preclinical studies from their immuno-oncology programs at the American Association for Cancer Research (AACR) 2014 Immunology and Immunotherapy Meeting taking place December 1-4, 2014 in Orlando, Florida. Presentations include: Clinical results from the Ad-RTS-hIL-12 + veledimex studies in patients with advanced breast cancer and melanoma demonstrating local and systemic IL-12-mediated anti-cancer activity, as well as safety through control of both immune- and IL-12-mediated toxicity with use of the RheoSwitch. Therapeutic System(R) (RTS(R)) gene switch (Abstract #B11); Preclinical data supporting the potential for cytolytic activity against solid tumor targets with allogeneic, genetically-modified stem cells enabled for controlled release of cell-linking moieties (CLMs) within the tumor micro-environment (Abstract #B25); and Preclinical data describing the development of a novel, high-throughput screening technology for rapidly identifying bi-specific antibodies capable of inducing targeted immunologic activity through the activation of T-cells or other immune cells against tumors (Abstract #B16). Interim clinical trial results continue to validate dose-dependent oral veledimex control of the Interleukin-12 (IL-12) gene program module and the rapid reversibility of cytokine expression and associated adverse events in patients upon withdrawal of the activator ligand. Together the Companies intend to integrate this RTS-hIL-12 veledimex-controlled cytokine module into a suite of next generation cellular products armed with tumor specific targeting and signaling through chimeric antigen receptor (CAR), T-Cell Receptor (TCR), and cell linking moiety (CLM) platforms. In two open-label Phase II clinical studies, twelve patients with metastatic advanced stage breast cancer and twenty-six patients with metastatic melanoma were administered Ad-RTS-hIL-12, a novel DNA-based therapeutic candidate for the controlled expression of IL-12, a potent cytokine for stimulating an anti-cancer T-cell immune response. Following intra-tumoral injection of Ad--RTS--hIL--12, expression of IL-12 within patients was controlled by the RheoSwitch Therapeutic System(R) (RTS(R)) gene switch using the oral activator ligand, veledimex, at doses ranging from 5mg to 160mg. All subjects had heavy tumor burden and disease progression at the time of enrollment, with mean number of prior therapies at 14 and 10 for breast cancer and melanoma patients, respectively. Treatment with Ad-RTS-hIL-12 + veledimex resulted in an increase in the immune cytokine IL-12 and downstream cytokines, IFNg, IP-10 and IL-10, resulting in a significant increase in the number of CD8+ T-cells. Among seven evaluable subjects in the Phase II clinical study of Ad-RTS-IL-12 + veledimex in patients with recurrent or metastatic breast cancer, three had stable disease, including one triple negative BC subject who crossed the primary endpoint of 16 week progression free survival, for a disease control rate (stable disease or better) of 43%. Target lesions and tumor burden were significantly reduced in approximately 40% of patients. In the Phase I/II study of Ad-RTS-hIL-12 + veledimex in subjects with unresectable stage III/IV melanoma, of eighteen evaluable subjects, one had a partial response and six had stable disease, for a disease control rate of 39%. In melanoma patients for whom a response was observed, there was evidence of local and systemic anti-cancer activity.

ZIOPHARM Oncology, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 02:00 PM

ZIOPHARM Oncology, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 02:00 PM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Jonathan J. Lewis, Chief Executive Officer and Director.

ZIOPHARM Oncology, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2014

ZIOPHARM Oncology, Inc. reported earnings results for the third quarter ended September 30, 2014. For the quarter, the company reported revenue of $633,000 against $200,000 a year ago. Loss from operations was $11,942,000 against $9,115,000 a year ago. Net loss was $6,093,000 against $16,713,000 a year ago. Basic and diluted net loss per share was $0.06 against $0.20 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZIOP:US $4.76 USD +0.07

ZIOP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $7.57 USD +0.50
Dynavax Technologies Corp $15.35 USD +0.30
Genocea Biosciences Inc $7.42 USD -0.11
GenVec Inc $2.04 USD -0.0028
Inovio Pharmaceuticals Inc $9.11 USD -0.09
View Industry Companies
 

Industry Analysis

ZIOP

Industry Average

Valuation ZIOP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 387.7x
Price/Book 13.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 359.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZIOPHARM ONCOLOGY INC, please visit www.ziopharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.